Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
62756-0093-40 62756-0093 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec 7, 2012 Jan 31, 2017 No Longer Used
67457-0246-00 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Apr 12, 2013 In Use
00781-9164-75 00781-9164 Octreotide Acetate Octreotide Acetate Hormonal Therapy Somatostatin Analog Oct 21, 1988 Jun 29, 2014 No Longer Used
00781-3165-75 00781-3165 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct 21, 1988 Nov 30, 2016 In Use
62756-0352-40 62756-0352 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug 14, 2007 Jan 31, 2017 No Longer Used
00078-0183-25 00078-0183 Octreotide Acetate Sandostatin 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Oct 21, 1988 Jul 31, 2019 No Longer Used
62756-0351-44 62756-0351 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug 14, 2007 Nov 30, 2016 No Longer Used
63323-0378-05 63323-0378 OCTREOTIDE ACETATE Octreotide 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Mar 14, 2006 In Use
00781-3167-71 00781-3167 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Feb 4, 2014 Feb 4, 2014 In Use
50242-0070-86 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 4, 2013 In Use
50242-0070-01 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 1, 2013 In Use
83047-0410-04 83047-0410 Obecabtagene autoleucel AUCATZYL 10000000.0 /1, 100000000.0 /1, 300000000.0 /1 Immunotherapy CAR-T CD19 Intravenous Nov 8, 2024 In Use
81481-0803-01 81481-0803 Nogapendekin alfa inbakicept-pmln ANKTIVA 400.0 ug/.4mL Immunotherapy Cytokine IL-15 (⍺,β,ɣ) Intravesical May 6, 2024 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 30, 2021 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-3774-12 00003-3774 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 8, 2017 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
00003-6120-01 00003-6120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Jan 2, 2025 In Use
82448-0150-14 82448-0150 Nirogacestat OGSIVEO 150.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
82448-0100-14 82448-0100 Nirogacestat OGSIVEO 100.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
82448-0050-18 82448-0050 Nirogacestat OGSIVEO 50.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
69656-0103-90 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Mar 27, 2017 May 31, 2022 No Longer Used
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use

Found 11564 results — Export these results